Astron Corp Ltd
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 135
- Market Cap
- -
- Introduction
AptarGroup, Inc. engages in the design, manufacture, drug delivery, consumer product dispensing, sealing and active packaging solutions, and services for the prescription drug, consumer health care, injectable, active packaging, beauty, personal care, home care, and food and beverages industries. It operates through the following segments: Pharma, Beauty and Home, and Food and Beverage. The company was founded in 1940 and is headquartered in Crystal Lake, IL.
Aptar Launches Clinical Study to Validate SmartTrackâ„¢ Platform for Accelerating Generic Inhaler Approvals
Aptar's clinical study aims to validate its SmartTrackâ„¢ platform as an in-vitro-in-silico alternative to comparative clinical endpoint studies for generic inhaled drug products, potentially eliminating a major regulatory hurdle.
Rakovina Therapeutics Advances Novel AI-Discovered PARP1 and ATR Inhibitors for Hard-to-Treat Cancers
Rakovina Therapeutics presented preclinical data at AACR 2025 showcasing AI-discovered PARP1 inhibitors with improved metabolic stability and potential CNS penetration for brain malignancies.
Repare Therapeutics' Gynecological Cancer Trial Shows Mixed Results, Beigene Inks $1.5B Deal for MAT2A Inhibitor
Repare Therapeutics' phase I trial of lunresertib and camonsertib in gynecological cancers with specific biomarkers showed mixed results, impacting stock prices.
Repare Therapeutics' Lunre+Camo Shows Promise in Gynecologic Cancers
Repare Therapeutics' MYTHIC Phase 1 trial shows Lunre+Camo achieved a 25.9% ORR in endometrial cancer and 37.5% in platinum-resistant ovarian cancer.
Aprea Therapeutics Optimizes ATRN-119 Dosing in Phase 1/2a Trial for Advanced Solid Tumors
Aprea Therapeutics initiates twice-daily dosing of ATRN-119 at 550mg in the ABOYA-119 Phase 1/2a trial to maintain optimal therapeutic levels.
Repare Therapeutics to Present Phase 1 MYTHIC Trial Data of Lunresertib and Camonsertib Combination in Advanced Cancers
Repare Therapeutics will present Phase 1 MYTHIC trial data for lunresertib combined with camonsertib in platinum-resistant ovarian and endometrial cancers.
Repare Therapeutics and NCI Collaborate to Advance Camonsertib Development
Repare Therapeutics and the National Cancer Institute (NCI) have entered a Cooperative Research and Development Agreement (CRADA) to further develop camonsertib.
Aprea Therapeutics Advances WEE1 and ATR Inhibitors in Clinical Trials
Aprea Therapeutics is progressing its Phase 1 ACESOT-1051 trial of APR-1051, a WEE1 inhibitor, showing promising tolerability in treating cancers with Cyclin E over-expression.
Repare Therapeutics' Optimized Dosing Strategy Mitigates Anemia in MYTHIC Trial
Repare Therapeutics presented data on an individualized dosing schedule of lunresertib and camonsertib in the Phase 1 MYTHIC trial.
Aptar's N-Sorb Nitrosamine Mitigation Solution Accepted into FDA's Emerging Technology Program
Aptar's N-Sorb, utilizing the 3-Phase Activ-Polymerâ„¢ platform, has been accepted into the FDA's Emerging Technology Program, signaling a significant advancement in pharmaceutical safety.